{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T05:26:36Z","timestamp":1764912396316,"version":"3.46.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Grade 3(G3) type I gastric neuroendocrine tumors (NETs) are rare, with only three documented cases in the literature to our knowledge. The case we report involves a type I gastric NET(g-NET) classified as G3, which exhibits heterogeneity in TP53 gene mutations. This suggests that G3 g-NETs may develop from G2 forms. In this tumor located in the gastric body, both G2 and G3 components coexist. The G2 component is found in the superficial mucosa and submucosa, while the G3 component is in the submucosa and muscularis propria. Genetic testing reveals that the TP53 gene is mutated in the G3 component. The coexistence of these alterations within a single primary tumor is extremely rare, indicating that the TP53 gene plays a crucial role in the progression from G2 NET to G3 NET. This case may challenge our previous understanding of g-NETs.<\/jats:p>","DOI":"10.3389\/fonc.2025.1708609","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T05:13:13Z","timestamp":1764911593000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case report: TP53 heterogeneous alteration in grade 3 type I gastric NET: a case implicating primary tumor progression"],"prefix":"10.3389","volume":"15","author":[{"given":"Yan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuekui","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjuan","family":"Ti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000003637","article-title":"Gastric neuroendocrine neoplasms: updated epidemiology and externally validated prognostic nomogram","author":"Zhao","year":"2025","journal-title":"Int J Surg"},{"key":"B2","article-title":"Chinese society of clinical oncology. Chinese expert consensus on gastrointestinal pancreatic neuroendocrine tumors (2016 edition)","volume":"21","year":"2016","journal-title":"Chin J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17599","article-title":"A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in China","volume":"8","author":"Fan","year":"2017","journal-title":"Oncotarget"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the\u00a02022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0548","article-title":"Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: A pathway distinct from poorly differentiated neuroendocrine carcinomas","volume":"22","author":"Tang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000662","article-title":"A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas","volume":"40","author":"Tang","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1159\/000511905","article-title":"A consensus-developed morphological re-evaluation of 196 high-grade gastroenteropancreatic neuroendocrine neoplasms and its clinical correlations","volume":"111","author":"Elvebakken","year":"2021","journal-title":"Neuroendocrinology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-024-09835-y","article-title":"Progression of low-grade neuroendocrine tumors (NET) to high-grade neoplasms harboring the NEC-like co-alteration of RB1 and TP53","volume":"35","author":"Joseph","year":"2023","journal-title":"Endocr Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-021-03202-6","article-title":"An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features","volume":"480","author":"Kasajima","year":"2022","journal-title":"Virchows Arch"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2019.06.08","article-title":"Genomic dissection of\u00a0gastrointestinal and lung neuroendocrine neoplasm","volume":"31","author":"Wang","year":"2019","journal-title":"Chin J Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/his.14230","article-title":"Programmed cell death protein 1\/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma","volume":"78","author":"Yamashita","year":"2020","journal-title":"Histopathology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-17-0560","article-title":"Genomic landscape of pancreatic neuroendocrine tumors: the International Cancer Genome Consortium","volume":"236","author":"Mafficini","year":"2018","journal-title":"J Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1158\/21598290.CD-21-0669","article-title":"Comprehensive genomic profiling of neuroendocrine carcinomas of the gastrointestinal system","volume":"12","author":"Yachida","year":"2022","journal-title":"Cancer Discov"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100065","article-title":"Integrated genomic and clinicopathologic approach distinguishes pancreatic grade 3 neuroendocrine tumor from neuroendocrine carcinoma and identifies a subset with molecular overlap","volume":"36","author":"Umetsu","year":"2023","journal-title":"Mod Pathol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e13257","DOI":"10.1111\/jne.13257","article-title":"Expression of p53 and Rb reveal subtypes of gastric neuroendocrine carcinoma with distinct prognosis","volume":"35","author":"Xing","year":"2023","journal-title":"J\u00a0Neuroendocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2946","article-title":"Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets","volume":"22","author":"Rekhtman","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-024-09827-y","article-title":"Rapid evolution of metastases in patients with treated G3 neuroendocrine tumors associated 55with NEC-like transformation and TP53 mutation","volume":"35","author":"Atsuko","year":"2024","journal-title":"Endocr Pathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800176","article-title":"Divergent cyclin B1 expression and Rb\/p16\/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors","volume":"17","author":"Igarashi","year":"2004","journal-title":"Modern Pathol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/his.14679","article-title":"Comparative study of rb1, cyclin d1 and p16 immunohistochemistry expression to distinguish lung small-cell carcinoma and large-cell neuroendocrine carcinoma","volume":"81","author":"Papaxoinis","year":"2022","journal-title":"Histopathology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/10668969241308228","article-title":"KRT20-\/SATB2+\/MCPyV+ Sinonasal merkel cell carcinoma: A detailed immunohistochemical and in situ hybridization study","volume":"33","author":"Rocha","year":"2025","journal-title":"Int J Surg Pathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030775","article-title":"Somatostatin receptor 2 expression profiles and their correlation with the efficacy of somatostatin analogues in gastrointestinal neuroendocrine tumors","volume":"14","author":"Watanabe","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0017","article-title":"Tumor size and perineural invasion predict outcome of gastric high-grade neuroendocrine neoplasms","volume":"10","author":"Zhang","year":"2021","journal-title":"Endocr Connect"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol3880499","article-title":"Autoimmune gastritis: distinct histological and immunohistochemical findings before complete loss of oxyntic glands","volume":"15","author":"Torbenson","year":"2002","journal-title":"Modern Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2016.1236397","article-title":"Autoimmune metaplastic atrophic gastritis in Chinese: a study of 320 patients at a large tertiary medical center","volume":"52","author":"Zhang","year":"2016","journal-title":"Scand J Gastroentero"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12020717","article-title":"Chemotherapy in well differentiated neuroendocrine tumors (NET) G1, G2, and G3: A narrative review","volume":"12","author":"Zappi","year":"2023","journal-title":"J Clin Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1708609\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T05:13:16Z","timestamp":1764911596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1708609\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":27,"alternative-id":["10.3389\/fonc.2025.1708609"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1708609","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"article-number":"1708609"}}